Personalized therapeutic strategies in HER2-driven gastric cancer.
Stefano UghettoCristina MiglioreFilippo PietrantonioMaria ApicellaAnnalisa PetrelliLaura D'ErricoStefania DurandoDaniel Moya-RullSara E BellomoSabrina RizzolioTania CapelôaSalvatore RibisiMaurizio DegiuliRossella ReddavidIda RapaUberto FumagalliStefano De PascaleDario RiberoCarla BaronchelliGiovanni SgroiEmanuele RausaGian Luca BaiocchiSarah MolfinoStefania ManentiMaria BencivengaMichele SaccoClaudia CastelliSalvatore SienaAndrea Sartore-BianchiFederica TosiFederica MoranoAlessandra RaimondiMichele PrisciandaroAnnunziata GloghiniSilvia MarsoniAntonino SottileIvana SarottoAnna SapinoCaterina MarchiòPaola CassoniSimonetta GuarreraSimona CorsoSilvia GiordanoPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2021)
These preclinical randomized trials clearly indicate that in HER2-driven gastric tumors, a boosted HER2 therapeutic blockade is required for optimal efficacy, leading to complete and durable responses in most of the cases. Our results suggest that a selected subpopulation of HER2-"hyper"-amplified GC patients could strongly benefit from this strategy. Despite the negative results of clinical trials, the dual blockade should be reconsidered for patients with clearly HER2-addicted cancers.